Linker Information
General Information of This Linker
| Linker ID |
LIN0ZXIJW
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Caproyl acid
|
|||||
| Linker Type |
Uncleavable linker
|
|||||
| Antibody-Linker Relation |
Uncleavable
|
|||||
| Structure |
|
|||||
| Formula |
C6H12O2
|
|||||
| Isosmiles |
CCCCCC(O)=O
|
|||||
| InChI |
InChI=1S/C6H12O2/c1-2-3-4-5-6(7)8/h2-5H2,1H3,(H,7,8)
|
|||||
| InChIKey |
FUZZWVXGSFPDMH-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
116.16
|
Polar area
|
37.3
|
||
|
Complexity
|
62.4385619
|
xlogp Value
|
1.6513
|
|||
|
Heavy Count
|
8
|
Rot Bonds
|
4
|
|||
|
Hbond acc
|
1
|
Hbond Donor
|
1
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
Aprutumab ixadotin [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Advanced solid tumors from cancer indications known to be FGFR2-positive, which were refractory to any standard therapy or had no standard therapy available, patients were required to have measurable disease, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1, an expected lifespan of at least 12 weeks.
|
||||
| Administration Dosage |
The starting dose was 0.1 mg/kg body weight, with doses increased in two-fold increments up to 0.80 mg/kg, after which the dose was escalated in 0.50 mg/kg increments, intravenously on day 1 of every 21-day cycle.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02368951 | Clinical Status | Phase 1 | ||
| Clinical Description |
An open-label,phase 1, dose-escalation trial to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetic, and pharmacodynamics of the anti-FGFR2 antibody drug conjugate BAY1187982 in subjects with advanced solid tumors known to express FGFR2.
|
||||
| Primary Endpoint |
Primary endpoints included safety, tolerability, and The MTD was determined to be 0.20 mg/kg.
|
||||
| Other Endpoint |
Secondary endpoints were pharmacokinetic evaluation and tumor response to aprutumab ixadotin.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligibility requires age ≥18, ECOG 0-1, advanced FGFR2+ solid tumors refractory to standard therapy (MTD expansion limited to triple-negative breast cancer ≤4 prior lines). Exclusion covers hypersensitivity to monoclonal antibodies, recent (<4 weeks) anticancer therapy, unresolved treatment-related toxicity, active brain metastases, significant cardiac disease, coagulation disorders, and pregnancy/breastfeeding.
Click to Show/Hide
|
||||
| Administration Dosage |
A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the starting dose based on toxicology data. The investigational drug will be administered as a 1-hour IV infusion once every 21 days at the trial site (Day 1 of each 21-day Cycle). The maximum possible dose escalation will be 2-fold and not more than 0.5 mg/kg BW until maximum tolerated dose is selected
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02368951 | Clinical Status | PHASE1 | ||
| Clinical Description |
An Open-label,Phase I, Dose-escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetic, and Pharmacodynamics of the Anti-FGFR2 Antibody Drug Conjugate BAY1187982 in Subjects With Advanced Solid Tumors Known to Express FGFR2.
|
||||
| Primary Endpoint |
The trial focuses on identifying the maximum tolerated dose (MTD) of the investigational drug, defined as the highest dose with <20% dose-limiting toxicities (DLTs) during Cycle 1. Safety and tolerability endpoints include adverse events (AEs) and serious adverse events (SAEs) monitored for up to 2 years.
|
||||
| Other Endpoint |
Pharmacokinetic (PK) assessments include single- and multiple-dose Cmax, AUC (0-tlast), AUC (0-504), and AUC (0-inf) over specified cycles (1, 3, 5, etc.). Biological markers FGFR2, CK18, and nucleosome levels in tumor/plasma are evaluated at screening and treatment milestones. Anti-drug antibodies (ADAs) and tumor response per RECIST are measured to assess immunogenicity and efficacy.
Click to Show/Hide
|
||||
References